Truist Financial
EBS icon

Truist Financial’s Emergent Biosolutions EBS Stock Holding History

Truist Financial’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-24,500
Closed -$216K – 2787
2025
Q3 		$216K Sell
24,500
-9,000
-27% -$70K ﹤0.01% 2513
2025
Q2 		$214K Buy
+33,500
New +$192K ﹤0.01% 2392

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
PGCM
Prescott Group Capital Management Tulsa, Oklahoma $1.16B AUM 53.61% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
VFA
Values First Advisors Gray, Tennessee $219M AUM 33.32% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Truist Financial's EBS Position: Q2 2026 in Review

Truist Financial reduced its Emergent Biosolutions (EBS) stake by 41% in Q2 2026, selling an estimated $254K and leaving 43,671 shares worth $366K. The position accounts for ﹤0.01% of the portfolio, ranked #2420.

Truist Financial first reported a position in EBS in Q3 2020 and has held it in 15 quarters since. The position peaked at $2.71M in Q4 2025. 68 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

  • Truist Financial held 43,671 shares of Emergent Biosolutions worth $366K as of Q2 2026.
  • Truist Financial sold 30,362 Emergent Biosolutions shares in Q2 2026, an estimated $254K.
  • Emergent Biosolutions made up ﹤0.01% of Truist Financial's portfolio in Q2 2026, its #2420 holding.
  • Truist Financial first reported a position in Emergent Biosolutions in Q3 2020 and has held it in 15 quarters since.
  • Truist Financial's Emergent Biosolutions position peaked at $2.71M in Q4 2025.
  • 68 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.